Home Newsfeeds Vertical Research Downgrades Stanley Black & Decker to Hold

Vertical Research Downgrades Stanley Black & Decker to Hold

Vertical Research analyst Jeffrey Sprague downgrades Stanley Black & Decker (NYSE:SWK) from Buy to Hold.

byBenzinga Newsdesk

July 29, 2022

1 minute read

Vertical Research analyst Jeffrey Sprague downgrades Stanley Black & Decker (NYSE:SWK) from Buy to Hold.

Analyst Ratings

Analyst Expectations for Celanese’s Future

By Benzinga Insights

May 11, 4:01 PM

Within the last quarter, Celanese (NYSE:CE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

Donald Trump NFTs Lose 73% Value In A Month As Investor Interest Wanes

By Mehab Qureshi

January 16, 8:57 AM

Donald Trump Digital Trading NFT cards have plummeted by a whooping 73% since their initial launch on Dec. 16. What Happened: After a historic low in activity, the floor price of Trump NFTs has plummeted to just $0.181 Ethereum (CRYPTO: ETH).

$MATIC

Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy’s Garden And More

By Lara Goldstein

July 19, 6:43 PM

GOP-Controlled House Committee Blocks All Cannabis & Psychedelics Amendments To Defense Bill: Now, No Floor Vote

DRUG

Applied Molecular Transport Completes Enrollment Of Phase 2 LOMBARD Monotherapy Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis

By Benzinga Newsdesk

September 20, 8:01 AM

Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with

AMTI

Vertical Research Downgrades Stanley Black & Decker to Hold

Related Posts

Analyst Expectations for Celanese’s Future

Donald Trump NFTs Lose 73% Value In A Month As Investor Interest Wanes

Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy’s Garden And More

Applied Molecular Transport Completes Enrollment Of Phase 2 LOMBARD Monotherapy Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis